EGFR Pathway Polymorphisms and Bladder Cancer Susceptibility and Prognosis

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2009 Apr 18

PMID 19372140

Citations 22

Authors

Rebecca A Mason

Elaine V Morlock

Margaret R Karagas

Karl T Kelsey

Carmen J Marsit

Alan R Schned

Angeline S Andrew

Affiliations

Soon will be listed here.

Abstract

The epidermal growth factor receptor (EGFR) pathway has recently been appreciated as a central mediator of tumorigenesis and an important drug target; however, the influence of genetic variation in this pathway on bladder cancer is not understood. Pathway activation leads to cell proliferation, angiogenesis and is antiapoptotic. We sought to test the hypothesis that bladder cancer susceptibility and survival are modified by inherited variations in the sequence of the EGFR and its pathway members. We tested associations using a population-based study of 857 bladder cancer cases and 1191 controls from New Hampshire. Multifactor dimensionality reduction software was used to predict gene-gene interactions. We detected an increased risk of bladder cancer associated with variant genotypes for the single nucleotide polymorphisms EGFR_03 [adjusted odds ratio (OR) 1.7 (95% confidence interval (CI) 1.0-2.8)] and EGFR_05 [adjusted OR 1.5 (95% CI 1.0-2.1)] compared with wild-type. EGFR variants experienced longer survival than those with wild-type alleles [e.g. adjusted hazard ratio EGFR_1808 0.3 (95% CI 0.1-0.9)]. In contrast, the variant form of the ligand, EGF_04, had worse survival [adjusted hazard ratio 1.5 (95% CI 1.0-2.3)] compared with wild-type. Our findings suggest modified bladder cancer risk and survival associated with genetic variation in the EGFR pathway. Understanding these genetic influences on increased bladder cancer susceptibility and survival may help in cancer prevention, drug development and choice of therapeutic regimen.

Citing Articles

The Role of Emodin in the Treatment of Bladder Cancer Based on Network Pharmacology and Experimental Verification.

Liu F, Li J, Zhou B, Shen Y, Tang J, Han J Comb Chem High Throughput Screen. 2024; 27(11):1661-1675.

PMID: 38504574 DOI: 10.2174/0113862073294990240122140121.

Two independent variants of epidermal growth factor receptor associated with risk of glioma in a Korean population.

Baek I, Cheong H, Namgoong S, Kim J, Kang S, Yoon S Sci Rep. 2022; 12(1):19014.

PMID: 36347915 PMC: 9643523. DOI: 10.1038/s41598-022-23217-6.

Two missense variants of the epidermal growth factor receptor gene are associated with non small cell lung carcinoma in the subjects from Iraq.

Lawi Z, Al-Shuhaib M, Ben Amara I, Alkhammas A Mol Biol Rep. 2022; 49(12):11653-11661.

PMID: 36169894 DOI: 10.1007/s11033-022-07933-w.

Polymorphisms in Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradiotherapy.

Butkiewicz D, Krzesniak M, Gdowicz-Klosok A, Giglok M, Marszalek-Zenczak M, Suwinski R Int J Mol Sci. 2021; 22(11).

PMID: 34070597 PMC: 8197839. DOI: 10.3390/ijms22115605.

Role of tyrosine kinases in bladder cancer progression: an overview.

Zangouei A, Barjasteh A, Rahimi H, Mojarrad M, Moghbeli M Cell Commun Signal. 2020; 18(1):127.

PMID: 32795296 PMC: 7427778. DOI: 10.1186/s12964-020-00625-7.

References

Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer A, Strange R . Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002; 359(9304):397-401. DOI: 10.1016/S0140-6736(02)07600-6. View

Zhou Q, Cheung Y, Jada S, Lim W, Kuo W, Gray J . EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther. 2006; 5(11):1445-9. DOI: 10.4161/cbt.5.11.3457. View

Pore N, Jiang Z, Gupta A, Cerniglia G, Kao G, Maity A . EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006; 66(6):3197-204. DOI: 10.1158/0008-5472.CAN-05-3090. View

Howe D, Lynas C . The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica. 2001; 86(6):563-9. View

Schilder R, Sill M, Chen X, Darcy K, Decesare S, Lewandowski G . Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005; 11(15):5539-48. DOI: 10.1158/1078-0432.CCR-05-0462. View

Teixeira A, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A . Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res. 2008; 14(11):3367-71. DOI: 10.1158/1078-0432.CCR-07-5119. View

Ritchie M, Hahn L, Roodi N, BAILEY L, Dupont W, Parl F . Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001; 69(1):138-47. PMC: 1226028. DOI: 10.1086/321276. View

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P . Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007; 4(4):e125. PMC: 1876407. DOI: 10.1371/journal.pmed.0040125. View

10.

Kang D, Gridley G, Huang W, Engel L, Winn D, Brown L . Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet Genomics. 2005; 15(5):343-7. DOI: 10.1097/01213011-200505000-00010. View

11.

Petty W, Dragnev K, Memoli V, Ma Y, Desai N, Biddle A . Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res. 2004; 10(22):7547-54. DOI: 10.1158/1078-0432.CCR-04-1169. View

12.

Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y . Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002; 23(2):257-64. DOI: 10.1093/carcin/23.2.257. View

13.

Ye Y, Yang H, Grossman H, Dinney C, Wu X, Gu J . Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008; 112(11):2467-74. DOI: 10.1002/cncr.23472. View

14.

Dominguez-Escrig J, Kelly J, Neal D, King S, Davies B . Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res. 2004; 10(14):4874-84. DOI: 10.1158/1078-0432.CCR-04-0034. View

15.

Tovar V, Villanueva A, Llovet J . [Cell biology and genetics in liver cancer]. Gastroenterol Hepatol. 2007; 30(6):360-9. DOI: 10.1157/13107573. View

16.

Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G . Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?. Clin Exp Metastasis. 2007; 24(2):79-86. DOI: 10.1007/s10585-007-9055-0. View

17.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2001; 37(6):443-8. DOI: 10.1159/000054076. View

18.

Coffey C, Hebert P, Ritchie M, Krumholz H, Gaziano J, Ridker P . An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics. 2004; 5:49. PMC: 419697. DOI: 10.1186/1471-2105-5-49. View

19.

Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J . Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res. 2004; 64(1):7-12. DOI: 10.1158/0008-5472.can-03-2623. View

20.

Kimura T, Maesawa C, Ikeda K, Wakabayashi G, Masuda T . Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncol Rep. 2006; 15(5):1205-10. View